dRural overall goal it to co-develop and implement a digital solution that delivers multiple services to rural citizens while creating opportunities economic growth and quality of life improvements. Then, to ensure the successful exploitation and sustainability after the project’s lifetime and its replication in other European territories. As such, our aspiration is to become the service marketplace of reference for European rural areas. dRural will build a service network for rural areas and communities based on four rural regions of Europe, namely: Extremadura (ES), Dubrovnik-Neretva County (HR) and Region Gelderland Midden (NL). Each of these settings are called regional demonstrators. The solution building will follow agile methodologies and ensure end-users co-creation and validation in each regional demonstrator. Besides, dRural will be developed with a 'by-design' approach to ethics, privacy, and data protection. An internet coverage optimization in the demonstrators will be done to guarantee a smooth deployment. Then, the solution will be set up in each region, guaranteeing its personalization and customization to the regional needs, and integrating with the local service providers. In parallel, an ecosystem of relevant players surrounding the dRural solution will be created in each region by identifying the key stakeholders, current problems and designing a value proposition for each of them. The ecosystem building exercise will be supported by an open call in each demonstrator leveraging financial support to third parties to incentivize the solution take up and expand the ecosystem of players involved. This will offer opportunities for entrepreneurs by promoting new market openings allowing also smaller and newer players to capture value. An evaluation of usage and impacts will be performed to ensure on-going support in the region after the project completionend.

ONCOVALUE will unlock the full potential of real world data (RWD) collected in European cancer hospitals and institutes to ease the decision-making of regulators on cost-effectiveness of novel cancer therapies. To achieve this, we build up data collection and processing capabilities of leading European cancer hospitals to create a high-quality clinical, quality of life, and adverse events data-sources. With the use powerful AI technologies, we will transform unstructured data originating from medical notes and medical images into structured data to enable analytics and real world evidence (RWE). This RWE will be directly available for clinicians for treatment management and for health regulatory and HTA bodies to adopt optimized data-driven methodologies for the effective assessment of medicinal products and digital health innovations. For that, we will provide an end-to-end infrastructure for RWD reporting in health regulatory and HTA decision-making and address the legal constraints in the cancer hospitals to ensure secure and legal access to RWD. Furthermore, ONCOVALUE will ensure the implementation of the developed guidelines and methodologies, by providing trainings for the collection and management of high-quality RWD in European cancer centres and for the analysis of this data by HTA and regulatory bodies. By opening the door to widespread regulatory and HTA integration of RWD, ONCOVALUE will lead to safer, more efficient, and affordable therapies, technologies, and digital solutions for (personalised) cancer care. As such, ONCOVALUE is positioned to contribute to increased cost-effectiveness and subsequent sustainability of cancer care. Systematic collection and evaluation of the patient reported outcomes will lead to improved well-being of the patients. Subsequently, on the long-term implementation of value-based cancer care at European cancer hospitals will aid in reducing the growing burden of cancer treatment in the EU and worldwide.